Agennix AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2008
2009
2010
2011
Cash & Short Term Investments
31,822.00
11,413.00
79,213.00
43,936.00
Total Accounts Receivable
1,349.00
134.00
340.00
3,133.00
Other Current Assets
1,298.00
756.00
1,423.00
2,673.00
Total Current Assets
34,469.00
12,303.00
80,976.00
49,742.00
Net Property, Plant & Equipment
524.00
3,416.00
3,462.00
3,678.00
Total Investments and Advances
136.00
140.00
143.00
145.00
Intangible Assets
3,584.00
91,881.00
99,466.00
101,962.00
Other Assets
10.00
17,543.00
28,667.00
400.00
Total Assets
38,723.00
140,926.00
239,371.00
183,575.00
ST Debt & Current Portion LT Debt
317.00
211.00
15,392.00
32.00
Accounts Payable
1,221.00
1,592.00
5,020.00
3,013.00
Income Tax Payable
251.00
347.00
122.00
45.00
Other Current Liabilities
4,225.00
4,815.00
4,872.00
5,029.00
Total Current Liabilities
6,014.00
6,965.00
25,406.00
8,119.00
Long-Term Debt
2,425.00
930.00
930.00
222.00
Deferred Taxes
-
15,850.00
7,631.00
6,950.00
Other Liabilities
7,380.00
15,676.00
26,675.00
-
Total Liabilities
15,819.00
55,064.00
87,299.00
42,939.00
Common Equity (Total)
22,904.00
85,862.00
152,072.00
140,636.00
Total Shareholders' Equity
22,904.00
85,862.00
152,072.00
140,636.00
Total Equity
22,904.00
85,862.00
152,072.00
140,636.00
Liabilities & Shareholders' Equity
38,723.00
140,926.00
239,371.00
183,575.00

About Agennix

View Profile
Address
Im Neuenheimer Feld 515
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.agennix.com
Updated 09/14/2018
Agennix AG is a biopharmaceutical company, which engages in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs include oral talactoferrin alfa and RGB-286638. The company was founded on November 5, 2009 and is headquartered in Heidelberg, Germany.